MODELING M-PROTEIN DYNAMICS IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING VENETOCLAX: UTILITY OF EARLY M-PROTEIN MONITORING TO PREDICT PROGRESSION FREE SURVIVAL

被引：0
|
作者：
Liu, S. [1 ]
Salem, A. [1 ]
Ross, J. [1 ]
Bueno, O. [1 ]
Badawi, M. [1 ]
机构：
[1] AbbVie, Chicago, IL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-059
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 50 条
  • [31] Simulation of Clinical Endpoints (Survival, PFS) in Patients With Refractory Multiple Myeloma Treated With Pomalidomide Based on Interim Week 8 M-protein Response
    Bruno, R.
    Jonsson, F.
    Zaki, M.
    Jacques, C.
    Richardson, P.
    Rajkumar, V. S.
    Claret, L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S647 - S647
  • [32] The impact on early diagnosis and survival outcome of M-protein screening-driven diagnostic approach to multiple myeloma in China: a cohort study
    Li, Jing
    Wang, Yue
    Liu, Peng
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E323 - E324
  • [33] High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
    J R Mills
    D R Barnidge
    A Dispenzieri
    D L Murray
    [J]. Blood Cancer Journal, 2017, 7 : e590 - e590
  • [34] High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
    Mills, J. R.
    Barnidge, D. R.
    Dispenzieri, A.
    Murray, D. L.
    [J]. BLOOD CANCER JOURNAL, 2017, 7 : e590 - e590
  • [35] Impacts of the COVID-19 Pandemic on Assessment of M-Protein and Free Light Chain Levels in Patients with Multiple Myeloma
    Roose, James
    Lu, Yichen
    Pierre, Amy E.
    Sawas, Ahmed
    Calip, Gregory S.
    [J]. BLOOD, 2022, 140 : 13191 - 13193
  • [36] Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma
    Oivanen, TM
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 1996, 57 (03) : 247 - 253
  • [37] Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone
    Otani, Yuki
    Zhao, Yunqi
    Wang, Guanyu
    Labotka, Richard
    Rogge, Mark
    Gupta, Neeraj
    Vakilynejad, Majid
    Bottino, Dean
    Tanigawara, Yusuke
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024,
  • [38] Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection
    McDonald, Zac
    Liyasova, Mariya
    Taylor, Paul
    Xu, Xin
    Gorospe, Kathleen
    Yao, Chenyu
    Liu, Qixin
    Yang, Liqiang
    Ma, Bin
    Piza, Jesus
    Reece, Donna E.
    Trudel, Suzanne
    [J]. BLOOD, 2019, 134
  • [39] Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone plus /- Elotuzumab
    Forslund, Ann
    Tang, Hao
    Duan, Chunzhe
    Popa-McKiver, Mihaela
    Berenson, James R.
    Robbins, Michael
    [J]. BLOOD, 2019, 134
  • [40] Predictive Significance of Serum Beta 2-Microglobulin Levels and M-Protein Velocity for Symptomatic Progression of Smoldering Multiple Myeloma
    Muta, Tsuyoshi
    Iida, Shinsuke
    Matsue, Kosei
    Sunami, Kazutaka
    Isoda, Jun
    Harada, Naoko
    Saburi, Yoshio
    Okamura, Seiichi
    Kumagae, Kyouya
    Watanabe, Junichi
    Kuroda, Junya
    Aoki, Kenichi
    Ogawa, Ryosuke
    Miyamoto, Toshihiro
    Akashi, Koichi
    Takamatsu, Yasushi
    [J]. BLOOD, 2014, 124 (21)
12345